This inventor holds 1 USPTO granted patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Joy Liu: Innovator in Hematopoietic Stem Cell Research
Introduction
Joy Liu is a notable inventor based in Boyds, MD (US). He has made significant contributions to the field of hematopoietic stem cell research. His innovative work focuses on enhancing the engraftment of these cells, which is crucial for successful transplantation procedures.
Latest Patents
Joy Liu holds a patent titled "Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells." This patent outlines methods for improving the engraftment of hematopoietic stem cells (HSC) in recipient subjects by reducing the expression or activity of CXC chemokine receptor 4 (CXCR4). The methods described can be utilized in gene therapy protocols and HSC transplantation, potentially allowing these procedures to occur without the need for radiation or chemotherapy conditioning, which is typically required in non-myeloablative HSC transplants. In some instances, gene editing techniques are employed to delete one copy of the CXCR4 gene prior to HSC or bone marrow transplantation, thereby enhancing the efficiency and durability of donor cell repopulation. Joy Liu has 1 patent to his name.
Career Highlights
Joy Liu is affiliated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work has been instrumental in advancing the understanding and application of hematopoietic stem cell therapies.
Collaborations
Joy Liu has collaborated with notable colleagues, including Philip M Murphy and Marie Siwicki, who is a woman. These collaborations have further enriched his research and contributions to the field.
Conclusion
Joy Liu's innovative work in hematopoietic stem cell research exemplifies the potential for advancements in medical therapies. His patent on enhancing engraftment through CXCR4 modulation is a testament to his commitment to improving patient outcomes in stem cell transplantation.